The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Bispecific T‐cell engagers for cancer immunotherapy
Open accessAbstract
Bispecific T‐cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two single‐chain variable fragments (scFv) connected in tandem by a flexible linker. One scFv binds to a T‐cell‐specific molecule, usually CD3, whereas the second scFv binds to a tumor‐associated antigen. This structure and specificity allows a BiTE to physically link a T cell to a tumor cell, ultimately stimulating T‐cell activation, tumor killing and cytokine production. BiTEs have been developed, which target several tumor‐associated antigens, for a variety of both hematological and solid tumors. Several BiTEs are currently in clinical trials for their therapeutic efficacy and safety. This review examines the salient structural and functional features of BiTEs, as well as the current state of their clinical and preclinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammarström, S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0119 · Cited by 1,300
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knop, S., Noppeney, R., Viardot, A., Hess, G., Schuler, M., et al. (2008) · Science · doi:10.1126/science.1158545 · Cited by 1,078
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Maus, M. V., Grupp, S. A., Porter, D. L., & June, C. H. (2014) · Blood · doi:10.1182/blood-2013-11-492231 · Cited by 616
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Baeuerle, P. A., & Reinhardt, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0547 · Cited by 592
Hybrid antibodies can target sites for attack by T cells
Staerz, U. D., Kanagawa, O., & Bevan, M. J. (1985) · Nature · doi:10.1038/314628a0 · Cited by 492
Topp, M. S., Gökbuget, N., Zugmaier, G., Degenhard, E., Goebeler, M.-E., Klinger, M., Neumann, S. A., Horst, H. A., Raff, T., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-07-441030 · Cited by 474
Klinger, M., Brandl, C., Zugmaier, G., Hijazi, Y., Bargou, R. C., Topp, M. S., Gökbuget, N., Neumann, S., Goebeler, M., Viardot, A., et al. (2012) · Blood · doi:10.1182/blood-2012-01-400515 · Cited by 471
A Theoretical Model of γ-Globulin Catabolism
BRAMBELL, F. W. R., HEMMINGS, W. A., & MORRIS, I. G. (1964) · Nature · doi:10.1038/2031352a0 · Cited by 449
Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P. T., Schwenkenbecher, J. M., Riethmüller, G., Dörken, B., & Bargou, R. C. (2000) · Blood · doi:10.1182/blood.v95.6.2098 · Cited by 445
Offner, S., Hofmeister, R., Romaniuk, A., Kufer, P., & Baeuerle, P. A. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.03.007 · Cited by 365
Mack, M., Riethmüller, G., & Kufer, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7021 · Cited by 351
Dreier, T., Lorenczewski, G., Brandl, C., Hoffmann, P., Syring, U., Hanakam, F., Kufer, P., Riethmuller, G., Bargou, R., & Baeuerle, P. A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10557 · Cited by 348
Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, C., Prang, N., & Baeuerle, P. A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20908 · Cited by 344
Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody
Perez, P., Hoffman, R. W., Shaw, S., Bluestone, J. A., & Segal, D. M. (1985) · Nature · doi:10.1038/316354a0 · Cited by 337
Bispecific antibodies for cancer therapy: The light at the end of the tunnel?
Chames, P., & Baty, D. (2009) · mAbs · doi:10.4161/mabs.1.6.10015 · Cited by 336
THE RELATIVE IMPACT AND FUTURE BURDEN OF PROSTATE CANCER IN THE UNITED STATES
CHAN, J. M., JOU, R. M., & CARROLL, P. R. (2004) · Journal of Urology · doi:10.1097/01.ju.0000142068.66876.53 · Cited by 303
Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., Offner, S., Locher, M., Urbig, T., Raum, T., et al. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.07.034 · Cited by 256
Lindhofer, H., Mocikat, R., Steipe, B., & Thierfelder, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.219 · Cited by 213
Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
Kipriyanov, S. M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.-W., Matys, E. R., & Little, M. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3156 · Cited by 202
Brischwein, K., Parr, L., Pflanz, S., Volkland, J., Lumsden, J., Klinger, M., Locher, M., Hammond, S. A., Kiener, P., Kufer, P., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156750c · Cited by 187
Laszlo, G. S., Gudgeon, C. J., Harrington, K. H., Dell’Aringa, J., Newhall, K. J., Means, G. D., Sinclair, A. M., Kischel, R., Frankel, S. R., & Walter, R. B. (2014) · Blood · doi:10.1182/blood-2013-09-527044 · Cited by 173
Chmielewski, M., Hombach, A. A., & Abken, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00371 · Cited by 167
Lutterbuese, R., Raum, T., Kischel, R., Hoffmann, P., Mangold, S., Rattel, B., Friedrich, M., Thomas, O., Lorenczewski, G., Rau, D., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000976107 · Cited by 166
Klein, J. S., Gnanapragasam, P. N. P., Galimidi, R. P., Foglesong, C. P., West, A. P., & Björkman, P. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811427106 · Cited by 163
Löffler, A., Gruen, M., Wuchter, C., Schriever, F., Kufer, P., Dreier, T., Hanakam, F., Baeuerle, P. A., Bommert, K., Karawajew, L., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402890 · Cited by 151
Friedrich, M., Raum, T., Lutterbuese, R., Voelkel, M., Deegen, P., Rau, D., Kischel, R., Hoffmann, P., Brandl, C., Schuhmacher, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0042 · Cited by 145
Friedrich, M., Henn, A., Raum, T., Bajtus, M., Matthes, K., Hendrich, L., Wahl, J., Hoffmann, P., Kischel, R., Kvesic, M., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0956 · Cited by 138
Cioffi, M., Dorado, J., Baeuerle, P. A., & Heeschen, C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1270 · Cited by 134
Schlegel, P., Lang, P., Zugmaier, G., Ebinger, M., Kreyenberg, H., Witte, K., Feucht, J., Pfeiffer, M. M., Teltschik, H., Kyzirakos, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.100073 · Cited by 132
Schlereth, B., Quadt, C., Dreier, T., Kufer, P., Lorenczewski, G., Prang, N., Brandl, C., Lippold, S., Cobb, K., Brasky, K., et al. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0001-1 · Cited by 103
Feldmann, A., Arndt, C., Töpfer, K., Stamova, S., Krone, F., Cartellieri, M., Koristka, S., Michalk, I., Lindemann, D., Schmitz, M., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200341 · Cited by 100
Herrmann, I., Baeuerle, P. A., Friedrich, M., Murr, A., Filusch, S., Rüttinger, D., Majdoub, M. W., Sharma, S., Kufer, P., Raum, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013474 · Cited by 85
Hammond, S. A., Lutterbuese, R., Roff, S. R., Lutterbuese, P., Schlereth, B., Bruckheimer, E., Kinch, M. S., Coats, S., Baeuerle, P. A., Kufer, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2760 · Cited by 82
Lutterbuese, R., Raum, T., Kischel, R., Lutterbuese, P., Schlereth, B., Schaller, E., Mangold, S., Rau, D., Meier, P., Kiener, P. A., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819b7c70 · Cited by 77
Osada, T., Hsu, D. S., Hammond, S. A., Hobeika, A. C., Devi, G. R., Clay, T. M., Lyerly, H. K., & Morse, M. A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605364 · Cited by 76
Formatting antibody fragments to mediate specific therapeutic functions
Weir, A. N. C., Nesbitt, A. M., Chapman, A. P., Popplewell, A. G., & Lawson, A. D. G. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300512 · Cited by 73
Zhang, T., & Sentman, C. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3200 · Cited by 65
Self-citationThe role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.
Weiner, G. J., Kostelny, S. A., Hillstrom, J. R., Cole, M. S., Link, B. K., Wang, S. L., & Tso, J. Y. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.5.2385 · Cited by 64
Amann, M., d’Argouges, S., Lorenczewski, G., Brischwein, K., Kischel, R., Lutterbuese, R., Mangold, S., Rau, D., Volkland, J., Pflanz, S., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181a1c097 · Cited by 64
Rodland, K., Bollinger, N., Ippolito, D. L., Opresko, L. K., Coffey, R. J., Zangar, R. C., & Wiley, H. S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800456200 · Cited by 60
Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies.
Bohlen, H., Manzke, O., Patel, B., Moldenhauer, G., Dörken, B., Fliedner, V. E. V., Diehl, V., & Tesch, H. (1993) · PubMed · Cited by 59
Yamamoto, K., Trad, A., Baumgart, A., Hüske, L., Lorenzen, I., Chalaris, A., Grötzinger, J., Dechow, T. N., Scheller, J., & Rose‐John, S. (2012) · Biochemical Journal · doi:10.1042/bj20120433 · Cited by 57
Kufer, P., Mack, M., Gruber, R., Lutterbüse, R., Zettl, F., & Riethmüller, G. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050431 · Cited by 51
Torisu‐Itakura, H., Schoellhammer, H. F., Sim, M., Irie, R. F., Hausmann, S., Raum, T., Baeuerle, P. A., & Morton, D. L. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182307fd8 · Cited by 41
Witthauer, J., Schlereth, B., Brischwein, K., Winter, H., Funke, I., Jauch, K., Baeuerle, P. A., & Mayer, B. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0185-0 · Cited by 23
Manzke, O., Titzer, S., Tesch, H., Diehl, V., & Bohlen, H. (1997) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050432 · Cited by 20
Trifunctional Triomab® Antibodies for Cancer Therapy
Lindhofer, H., Heß, J., & Ruf, P. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9_16 · Cited by 12
Cited by
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Immunotherapy and targeted therapy combinations in metastatic breast cancer
Esteva, F. J., Hubbard-Lucey, V. M., Tang, J., & Pusztai, L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30026-9 · Cited by 453
Metadata
- Authors
- Huehls, A. M., Coupet, T. A., & Sentman, C. L.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2014-11-04
- Volume
- 93
- Issue
- 3
- Pages
- 290-296
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2127132803
- Cited by
- 466
- References
- 49
- FWCI
- 11.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.